Evoke Wealth’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Evoke Wealth’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-468	Closed	-$2K	–	1275
2021 Q4	$2K	Hold	468	–	–	﹤0.01%	1087
2021 Q3	$2K	Hold	468	–	–	﹤0.01%	1043
2021 Q2	$3K	Hold	468	–	–	﹤0.01%	1016
2021 Q1	$3K	Hold	468	–	–	﹤0.01%	986
2020 Q4	$3K	Hold	468	–	–	﹤0.01%	853
2020 Q3	$3K	Hold	468	–	–	﹤0.01%	810
2020 Q2	$2K	Buy	+468	New	+$2.08K	﹤0.01%	919

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FIG

Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Evoke Wealth's PRTK Position: Q1 2022 in Review

Evoke Wealth sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 468 shares — an estimated $2K sold.

Evoke Wealth first reported a position in PRTK in Q2 2020 and held it in 7 quarters. The position peaked at $3K in Q2 2021. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Evoke Wealth reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Evoke Wealth sold 468 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $2K.
Evoke Wealth first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and held it in 7 quarters.
Evoke Wealth's Paratek Pharmaceuticals, Inc. position peaked at $3K in Q2 2021.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Evoke Wealth's 13F filing for Q1 2022, filed 10 May 2022.